Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02858258
Title ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Prof. Dr. M. Dreyling (co-chairman)
Indications

mantle cell lymphoma

Therapies

Cisplatin + Cytarabine + Dexamethasone + Filgrastim + Rituximab

Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries ITA | DEU


No variant requirements are available.